Next Article in Journal
In Silico Prediction of the Anti-Depression Mechanism of a Herbal Formula (Tiansi Liquid) Containing Morinda officinalis and Cuscuta chinensis
Next Article in Special Issue
From 2-Alkylsulfanylimidazoles to 2-Alkylimidazoles: An Approach towards Metabolically More Stable p38α MAP Kinase Inhibitors
Previous Article in Journal
Comparison of Dilution, Filtration, and Microwave Digestion Sample Pretreatments in Elemental Profiling of Wine by ICP-MS
Previous Article in Special Issue
Methylisoindigo and Its Bromo-Derivatives Are Selective Tyrosine Kinase Inhibitors, Repressing Cellular Stat3 Activity, and Target CD133+ Cancer Stem Cells in PDAC
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Current Development Status of MEK Inhibitors

Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300192, China
*
Author to whom correspondence should be addressed.
Molecules 2017, 22(10), 1551; https://doi.org/10.3390/molecules22101551
Submission received: 9 August 2017 / Revised: 11 September 2017 / Accepted: 12 September 2017 / Published: 26 September 2017
(This article belongs to the Special Issue Kinase Inhibitors)

Abstract

The current development status of mitogen-activated protein kinase kinase (MEK) inhibitors, including the preclinical data and clinical study progress, has been summarized in this review. Different MEK inhibitors, possessing specific physicochemical properties and bioactivity characteristics, may provide different options for patients seeking treatment for cancer. Moreover, the combination of the MEK inhibitors with other therapies—such as chemotherapy, targeted therapy, and immunotherapy—may be a promising approach for clinical use.
Keywords: MEK inhibitors; targeted therapy; combination; approved drug; clinical study; preclinical study MEK inhibitors; targeted therapy; combination; approved drug; clinical study; preclinical study

Share and Cite

MDPI and ACS Style

Cheng, Y.; Tian, H. Current Development Status of MEK Inhibitors. Molecules 2017, 22, 1551. https://doi.org/10.3390/molecules22101551

AMA Style

Cheng Y, Tian H. Current Development Status of MEK Inhibitors. Molecules. 2017; 22(10):1551. https://doi.org/10.3390/molecules22101551

Chicago/Turabian Style

Cheng, Ying, and Hongqi Tian. 2017. "Current Development Status of MEK Inhibitors" Molecules 22, no. 10: 1551. https://doi.org/10.3390/molecules22101551

APA Style

Cheng, Y., & Tian, H. (2017). Current Development Status of MEK Inhibitors. Molecules, 22(10), 1551. https://doi.org/10.3390/molecules22101551

Article Metrics

Back to TopTop